Molecular basis and targeted therapies for radioiodine refractory thyroid cancer

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Radioiodine-refractory thyroid cancer (RAIR-TC) presents a significant clinical challenge with a poor prognosis.
• Current treatment limitations stem from reduced sodium iodide symporter (Na+/I- symporter, NIS) expression or impaired trafficking.
• Effective identification and treatment selection for RAIR-TC patients remain critical unmet needs.

Purpose of the Study:

• To review and present updated clinical definitions of RAIR-TC based on iodine-131 uptake and therapeutic response.
• To explore the molecular mechanisms underlying loss of membrane-localized NIS in RAIR-TC.
• To provide a basis for developing novel therapeutic strategies for RAIR-TC patients.

Main Methods:

• Literature review of current clinical definitions and diagnostic criteria for RAIR-TC.
• Analysis of molecular alterations affecting NIS expression and localization.
• Discussion of emerging targeted therapies including tyrosine kinase inhibitors (TKIs), redifferentiation, and immunotherapy.

Main Results:

• Several associations have proposed updated definitions for RAIR-TC, focusing on iodine-131 uptake and tumor response.
• Molecular alterations in NIS expression and trafficking are key to understanding RAIR-TC.
• Emerging targeted therapies show promise for overcoming radioiodine refractoriness.

Conclusions:

• Clearer definitions of RAIR-TC aid in patient identification and treatment planning.
• Understanding the molecular basis of NIS loss is crucial for developing effective therapies.
• Targeted therapies, including TKIs, redifferentiation, and immune checkpoint inhibitors, represent promising avenues for RAIR-TC management.